Cambrian BioPharma Inc - Jul 10, 2023 Form 4 Insider Report for Sensei Biotherapeutics, Inc. (SNSE)

Role: 10%+ Owner
Signature: Cambrian BioPharma Inc, by: /s/ James Peyer
Stock symbol: SNSE
Transactions as of: Jul 10, 2023
Transactions value $: $0
Form type: 4
Date filed: 7/12/2023, 04:27 PM
Previous filing: Mar 7, 2023
Next filing: Aug 2, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SNSE	Common Stock	Award	$0	+4.47K	+0.09%	$0.00	5.24M	Jul 10, 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SNSE	Stock Option (Right to Buy)	Award	$0	+14.6K		$0.00	14.6K	Jul 10, 2023	Common Stock	14.6K	$1.22	Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or July 10, 2024, subject to the James Peyer's continuous service with the Issuer through such vesting date.
F2	These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.
F3	The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or July 10, 2024, subject to James Peyer's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to James Peyer's continuous service with the Issuer through such vesting date.